Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The monthly returns are then compounded to arrive at the annual return. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
#Co diagnostics inc co dx plus
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. These returns cover a period from Januthrough July 31, 2023. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. and Morningstar, Inc.Ĭopyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. XWELL, Inc.'s revenues are expected to be $11.65 million, down 60.3% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of -266.7%.
#Co diagnostics inc co dx free
( XWEL Quick Quote XWEL - Free Report), another stock in the same industry, has yet to report results for the quarter ended December 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. In terms of the Zacks Industry Rank, Medical Services is currently in the top 41% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.15 on $5.75 million in revenues for the coming quarter and -$0.55 on $24.75 million in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.
Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Co-Diagnostics, Inc. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Shares have added about 15.5% since the beginning of the year versus the S&P 500's gain of 1.4%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Ĭo-Diagnostics, Inc. The company has topped consensus revenue estimates just once over the last four quarters. This compares to year-ago revenues of $20.4 million. , which belongs to the Zacks Medical Services industry, posted revenues of $1.4 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 74.53%. Over the last four quarters, the company has surpassed consensus EPS estimates two times.Ĭo-Diagnostics, Inc. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%. This quarterly report represents an earnings surprise of -113.33%. These figures are adjusted for non-recurring items. This compares to earnings of $0.25 per share a year ago. ( CODX Quick Quote CODX - Free Report) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.15.
0 kommentar(er)
